Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings or view top-rated stocks.

8 brokers have issued 12 month price targets for Teva Pharmaceutical Industries' shares. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price.
View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.

Teva Pharmaceutical Industries' stock was trading at $8.01 at the beginning of the year. Since then, TEVA shares have increased by 8.1% and is now trading at $8.66.
View the best growth stocks for 2022 here.

Teva Pharmaceutical Industries saw a increase in short interest in September. As of September 15th, there was short interest totaling 25,940,000 shares, an increase of 28.0% from the August 31st total of 20,270,000 shares. Based on an average daily trading volume, of 13,920,000 shares, the short-interest ratio is presently 1.9 days.
View Teva Pharmaceutical Industries' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our TEVA earnings forecast.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted its quarterly earnings results on Tuesday, July, 26th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.09. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.82 billion. Teva Pharmaceutical Industries had a negative net margin of 6.83% and a positive trailing twelve-month return on equity of 25.68%.

Teva Pharmaceutical Industries issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $2.40-$2.60 for the period. The company issued revenue guidance of $15.00 billion-$15.60 billion, compared to the consensus revenue estimate of $15.67 billion.

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TEVA stock can currently be purchased for approximately $8.66.

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $9.62 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($0.95) on an earnings per share basis.

The company employs 37,537 workers across the globe.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.